Retatrutide: Breaking Barriers in Obesity Models

Background

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that simultaneously activates three receptors: GLP-1R, GIPR, and GCGR. It represents the current frontier of incretin pharmacology, extending the dual-agonism strategy pioneered by tirzepatide into triple-agonism for the first clinically validated time. Published trial data have reported body-weight reductions exceeding those observed with any previous single agent.

Molecular profile

• Sequence: 39-amino-acid synthetic peptide
• Modifications: Aib substitutions for DPP-4 resistance; C-20 fatty acid acylation for albumin binding (similar strategy to semaglutide and tirzepatide)
• Plasma half-life: approximately 6 days, supporting once-weekly dosing in clinical studies
• Receptor affinities: high-affinity agonism at GLP-1R, GIPR, and GCGR — with an engineered balance among the three

Three mechanisms, one molecule

Each receptor contributes distinct physiology. Retatrutide engages all three to produce complementary metabolic effects:

1. GLP-1 receptor agonism

• Appetite suppression via hypothalamic and hindbrain satiety circuits
• Delayed gastric emptying prolonging satiety
• Glucose-dependent insulin secretion potentiation
• Glucagon suppression during hyperglycemia

2. GIP receptor agonism

• Direct effects on adipose tissue — lipid storage and mobilization balance
• Amplification of insulin response
• Potential synergistic satiety via CNS GIPR
• Possible GI-tolerability benefit (trial-data-dependent)

3. GCGR (glucagon receptor) agonism

• Increased energy expenditure — thermogenic tone and metabolic rate elevation
• Hepatic lipid oxidation — reduction in hepatic triglyceride content
• Promotes amino acid catabolism
• Mobilizes glycogen (offset by GLP-1 insulin-secretory effect, keeping glucose in balance)

The engineering challenge is balancing GCGR activity so that hepatic glucose output isn't excessive. Too much GCGR action destabilizes glycemic control; too little and the thermogenic benefit is lost. Retatrutide's specific potency balance across the three receptors is what makes the design work.

What published trials have shown

Peer-reviewed clinical data (phase 1 and phase 2 results) have documented:

• Body weight reduction — approximately 24% over 48 weeks at the highest doses, exceeding any prior single-agent outcome
• Hepatic fat — substantial reduction in MRI-PDFF measured hepatic triglyceride content
• Glycemic effects — HbA1c reductions in type 2 diabetes cohorts
• Tolerability — GI side effects dose-dependent, similar class profile to GLP-1-containing agonists with titration needed
• Lipid profile — improvements in triglycerides, partly via GCGR-mediated hepatic effects

What laboratories typically study

• Receptor pharmacology — functional EC50 at all three receptors, bias coefficients, selectivity ratios
• Metabolic endpoints — glucose tolerance, body composition in DIO mice, DIO rats, NHP studies
• Hepatic biology — hepatic steatosis reversal, NAFLD/MASH models, liver-specific gene expression
• Energy expenditure — indirect calorimetry, thermogenic gene expression in adipose tissue (UCP1, PGC-1α)
• Adipose biology — browning markers, lipolysis-lipogenesis balance
• Comparative studies — vs semaglutide (mono), vs tirzepatide (dual)
• Safety pharmacology — cardiovascular, renal endpoints relative to class

Handling and quality

• Supplied as lyophilized powder (typical research format 10 mg)
• Store lyophilized at -20°C, protected from light
• Reconstitute with sterile/bacteriostatic water shortly before use
• Reconstituted solution stable ~4 weeks at 2–8°C
• Verify by HPLC (≥99.0%) with MS identity; request batch COA

Related reading

• /research/retatrutide — compound profile
• /blog/glp-1-gip-glucagon-metabolic-evolution — evolution of agonist classes
• /blog/glp-1-agonists-retatrutide-research-overview-benefits-models — broad class overview
• /blog/tirzepatide-dual-incretin-glp-1-gip-research — dual agonism predecessor
• /compare/semaglutide-vs-retatrutide — mono vs triple
• /compare/tirzepatide-vs-retatrutide — dual vs triple
• /category/weight-loss-research — catalog

RUO disclaimer

For laboratory research use only. Retatrutide is investigational and not approved for any human indication. Not for human consumption outside approved research settings.